Prime Editing of Vascular Endothelial Growth Factor Receptor 2 Attenuates Angiogenesis <i>In Vitro</i>

Vascular endothelial growth factor receptor (VEGFR)-2 is a key switch for angiogenesis, which is observed in various human diseases. In this study, a novel system for advanced prime editing (PE), termed PE6h, is developed, consisting of dual lentiviral vectors: (1) a clustered regularly interspaced palindromic repeat-associated protein 9 (H840A) nickase fused with reverse transcriptase and an enhanced PE guide RNA and (2) a dominant negative (DN) <i>MutL</i> homolog 1 gene with nicking guide RNA. PE6h was used to edit <i>VEGFR2</i> (c.18315T>A, 50.8%) to generate a premature stop codon (TAG from AAG), resulting in the production of DN-VEGFR2 (787 aa) in human retinal microvascular endothelial cells (HRECs). DN-VEGFR2 impeded VEGF-induced phosphorylation of VEGFR2, Akt, and extracellular signal-regulated kinase-1/2 and tube formation in PE6h-edited HRECs <i>in vitro</i>. Overall, our results highlight the potential of PE6h to inhibit angiogenesis <i>in vivo</i>.